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The chromatin remodelling factor chromodomain helicase
DNA-binding protein 4 (CHD4) is a catalytic subunit of the
NuRD transcriptional repressor complex. Here, we reveal
novel functions for CHD4 in the DNA-damage response
(DDR) and cell-cycle control. We show that CHD4
mediates rapid poly(ADP-ribose)-dependent recruitment
of the NuRD complex to DNA-damage sites, and we identi-
fy CHD4 as a phosphorylation target for the apical DDR
kinase ataxia-telangiectasia mutated. Functionally, we
show that CHD4 promotes repair of DNA double-strand
breaks and cell survival after DNA damage. In addition, we
show that CHD4 acts as an important regulator of the G1/S
cell-cycle transition by controlling p53 deacetylation.
These results provide new insights into how the chromatin
remodelling complex NuRD contributes to maintaining
genome stability.
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Introduction
In response to DNA damage, cells initiate a coordinated
programme of events, termed the DNA-damage response
(DDR), which is critical for maintenance of genome integrity
and the prevention of ageing and tumourigenesis (Harper and
Elledge, 2007; Jackson and Bartek, 2009). Upon detection of
DNA lesions, cells activate local and global DDR events that
promote cell-cycle checkpoint signalling and DNA repair.
Locally and adjacent to DNA-damage sites, DDR proteins
are recruited in an orchestrated manner. For example, in
response to DNA double-strand breaks (DSBs), phosphoryla-
tion of the histone variant H2AX by DDR protein kinases such
as ataxia-telangiectasia mutated (ATM) leads to recruitment
of the DDR mediator protein mediator of DNA-damage
checkpoint-1 (MDC1; Rogakou et al, 1998; Stucki et al,
2005). This then brings about further chromatin alterations
that permit recruitment of additional DDR mediators such as
p53-binding protein 1 (53BP1) and breast cancer 1 (BRCA1;
Panier and Durocher, 2009). DSBs, DNA single-strand breaks
(SSBs) and DNA nicks also activate poly(ADP-ribose) poly-
merase (PARP) enzymes that modify target proteins with
poly(ADP-ribose) chains (PAR chains) at DNA-damage sites,
thereby stimulating the recruitment and/or activity of repair
factors (Malanga and Althaus, 2005; Hakme et al, 2008;
Rouleau et al, 2010). Concomitantly, DNA damage induces
a global transcriptional programme that leads to the expres-
sion of genes whose products slow down or arrest cell-cycle
progression to facilitate DNA repair, or trigger programmed
cell death (Harper and Elledge, 2007; Jackson and Bartek,
2009). Central to this transcriptional response is activation of
the tumour suppressor p53 through post-translational modi-
ﬁcations that include p53 phosphorylation and acetylation
(Carter and Vousden, 2009; Kruse and Gu, 2009; Vousden and
Prives, 2009).
A critical parameter for initiating the DDR is the accessi-
bility of checkpoint and repair factors to DNA lesions within
chromatin (Misteli and Soutoglou, 2009). Indeed, compacted
chromatin can be refractory to full DDR activation (Murga
et al, 2007), and accumulating evidence suggests pivotal and
direct functions for chromatin remodelling factors in relieving
such inhibitory effects (Bao and Shen, 2007; Downs et al,
2007; Osley et al, 2007; Clapier and Cairns, 2009; van Attikum
and Gasser, 2009). Prominent among these is chromodomain
helicase DNA-binding protein 4 (CHD4; also known as Mi-
2b), an integral component of the NuRD complex (nucleo-
some remodelling deacetylase) that is unique in combining
chromatin remodelling activity with histone deacetylase and
demethylase functions involved in transcriptional repression
(Wade et al, 1998; Xue et al, 1998; Zhang et al, 1998; Denslow
and Wade, 2007; Ramirez and Hagman, 2009). Notably,
CHD4 is a likely target for DDR kinases (Matsuoka et al,
2007; Mu et al, 2007; Stokes et al, 2007), and loss of function
of CHD4 or other NuRD components causes accumulation of
DNA damage and features of accelerated ageing (Pegoraro
et al, 2009). In addition, CHD4-associated NuRD subunits
HDAC1 (histone deacetylase 1) and MTA2 (metastasis-
associated protein 2) have been implicated in regulating
p53 deacetylation and thereby p53 transcriptional activity
(Luo et al, 2000). Despite these ﬁndings, direct functions for
CHD4 in the DDR have not hitherto been described. Here, we
show that CHD4 is rapidly recruited to DNA lesions in a
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3130PARP-dependent manner and is phosphorylated by ATM in
response to DNA damage. We also establish that CHD4
controls cell-cycle progression by regulating p53-mediated
G1/S arrest, and promotes DSB repair and cell survival
after DNA-damage induction.
Results
CHD4 is recruited to DNA-damage sites as part of the
NuRD complex
To explore the involvement of CHD4 in the DDR, we ﬁrst
examined whether it was recruited to DNA lesions. When we
used laser micro-irradiation to generate localized DNA
damage in human U2OS cells, we observed CHD4 accumula-
tion in the damaged regions as revealed by its detection with
an anti-CHD4 antibody (Figure 1A; see Supplementary Figure
S1A for demonstration of antibody speciﬁcity). Notably, this
CHD4 re-localization was rapid but transient: CHD4 accumu-
lated at sites of micro-irradiation within a few minutes, but
staining intensity then quickly declined and was no longer
visible after 30min (Figure 1A). Similar results were obtained
in U2OS cells expressing epitope-tagged CHD4 as well as in
other cell types, including BJ primary human ﬁbroblasts,
mouse embryonic ﬁbroblasts (Supplementary Figure S1B–
D) and HeLa cervical carcinoma cells (data not shown).
Although CHD4 did not form detectable foci after cell
exposure to ionizing radiation (IR) or genotoxic drugs (data
not shown), CHD4 displayed enhanced resistance to
detergent extraction very early on after treating cells with
the DNA-damaging agent H2O2 (Supplementary Figure S1E),
consistent with CHD4 rapid recruitment to damaged chroma-
tin. Interestingly, other components of the NuRD complex—
including HDAC1 and MTA2—were also detected at sites of
laser-induced damage (Figure 1B). Moreover, CHD4 depletion
by short-interfering RNA (siRNA) treatment impaired both
HDAC1 and MTA2 recruitment to damaged regions
(Figure 1C; Supplementary Figure S2; note that CHD4
depletion did not affect expression levels of HDAC1 or
MTA2). In contrast, HDAC1 depletion did not impair CHD4
accrual at sites of DNA lesions (Figure 1D). Collectively, these
ﬁndings suggested that CHD4 is recruited to DNA-damage
sites as part of the NuRD complex and that CHD4 has a
leading function in NuRD recruitment.
CHD4 recruitment to DNA-damage sites is PARP
dependent
Having discovered the mobilization of CHD4 to DNA lesions,
we next sought to determine the mechanism for this. Initially,
we focused on the potential function of H2AX phosphoryla-
tion (gH2AX) because this histone modiﬁcation has pre-
viously been implicated in the recruitment of certain
chromatin remodelling factors to damaged chromatin in
yeast (van Attikum and Gasser, 2009). However, CHD4
accumulation at DNA-damage sites was not impaired in
H2AX-deﬁcient cells (Supplementary Figure S1D), suggesting
a different recruitment mode. We thus tested for the potential
contribution of two important enzymes involved in the early
steps of the DDR: ATM and PARP. Use of the ATM inhibitor
KU-55933 (Hickson et al, 2004) revealed that ATM activity
was dispensable for CHD4 recruitment to damage sites; in
fact, we consistently observed enhanced CHD4 recruitment
upon ATM inhibition (Figure 2A; Supplementary Figure S1B
and C; Supplementary Figure S3A shows that CHD4 protein
levels were not affected by ATM inhibition). In line with this,
CHD4 accumulation at DNA-damage sites was also observed
in ATM-deﬁcient A-T ﬁbroblasts (Figure 2A; Supplementary
Figure S3B). Similar results were obtained for Seckel syn-
drome cells (O’Driscoll et al, 2003) deﬁcient for the ATM-
related kinase ATR (data not shown).
In striking contrast to the above data, chemical inhibition
of the PARP1 and PARP2 enzymes with the compound
KU-58948 (Farmer et al, 2005) or PARP1/2 depletion by
RNA interference completely abrogated CHD4 accumulation
at sites of laser-induced damage (Figure 2A; Supplementary
Figure 1 CHD4 is recruited to sites of laser-induced DNA damage within the NuRD complex. (A) Immunodetection of CHD4 and gH2AX
(damage sites) at the indicated times after laser micro-irradiation in U2OS cells. (B) Recruitment of NuRD complex subunits to sites of laser-
induced DNA damage (labelled by gH2AX) 5min after micro-irradiation in U2OS cells. (C, D) Immunodetection of HDAC1 and CHD4 5min
after laser micro-irradiation in U2OS cells treated with the indicated siRNAs (siLuci: control). Cells were pre-treated with ATM inhibitor
to facilitate detection of HDAC1 and CHD4 lines. Lower panels show siRNA efﬁciency. In laser micro-irradiation experiments, detergent
pre-extraction was performed before ﬁxation of the cells for immunostaining. Scale bars, 10mm.
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PARP1/2 depletion did not affect CHD4 levels). As PARP1
and PARP2 are activated by DNA-strand breaks, this PARP
dependency of CHD4 recruitment strongly suggested that
CHD4 was speciﬁcally recruited to such structures. Consis-
tent with this idea, the rapid and transient recruitment of
CHD4 to DNA-damage sites mirrored the kinetics of poly
(ADP-ribosyl)ation (Supplementary Figure S1F). Moreover,
we found that CHD4 directly bound PAR chains (Figure 2B;
Supplementary Figure S3E), which concurs with CHD4
having a leading function in recruiting other NuRD subunits
to DNA-damage sites.
Although CHD4 does not display canonical PAR-binding
domains (Karras et al, 2005; Ahel et al, 2008), sequence
analyses revealed the presence of putative PAR-binding
motifs in the CHD4 amino- and carboxyl-terminal regions
that loosely matched a characterized consensus (Pleschke
et al, 2000; Gagne et al, 2008). By carrying out studies with
CHD4 deletion derivatives, we found that the amino-term-
inal, but not carboxyl-terminal, region displayed PAR binding
comparable with that exhibited by the full-length protein
(Figure 2B), and consistent with this, the CHD4 carboxyl-
terminal region displayed defective recruitment to DNA-
damage sites (Figure 2C). Taken together, these data showed
that CHD4 is rapidly and transiently recruited to damaged
chromatin within the NuRD complex. Furthermore, they
established that this recruitment occurs in a PARP-dependent
manner that likely involves CHD4 binding to PARylated
proteins, including PARP1 itself, present at damage sites.
CHD4 is phosphorylated upon DNA damage
in an ATM-dependent manner
Along with their recruitment to DNA-damage sites, another
hallmark of many DDR proteins is their post-translational
modiﬁcation in response to genotoxic stress. Interestingly,
proteomic screens in human cells have identiﬁed CHD4 as a
target for DDR kinases (Matsuoka et al, 2007; Mu et al,2 0 0 7 ;
Stokes et al, 2007). More speciﬁcally, we noted that one of the
putative phosphorylation sites on CHD4 that is conserved in
vertebrates (Ser-1346 in isoform 2; Figure 3A) was identiﬁed
by mass spectrometry (Matsuoka et al, 2007) and by bioin-
formatic analyses with a high-stringency search mode
(http://scansite.mit.edu/). By using a phospho-speciﬁc anti-
body raised against the corresponding motif (GpSQE), we
found that transiently expressed HA-CHD4 was indeed phos-
phorylated in human cells, and that this phosphorylation was
markedly increased in response to IR, in a dose- and time-
dependent manner (Figure 3A; Supplementary Figure S4A
and data not shown). Similarly, we detected phosphorylation
of endogenous CHD4 when cells were treated with DNA-
damaging agents such as H2O2 and neocarzinostatin
(Supplementary Figure S4B and data not shown).
Importantly, detection of CHD4 phosphorylation was abro-
gated when Ser-1346 was mutated to Ala (SA; Figure 3A).
Furthermore, we found that this CHD4 phosphorylation was
prevented when cells were incubated with Wortmannin
(Sarkaria et al, 1998) or the ATM inhibitor KU-55933
(Hickson et al, 2004), but not the DNA-PK inhibitor
NU-7441 (Leahy et al, 2004) (see Figure 3B; Supplementary
Figure S4B). Collectively, these results showed that CHD4
is phosphorylated after DNA damage on Ser-1346 in an
ATM-dependent manner.
We next investigated possible connections between
ATM-dependent phosphorylation of CHD4 and its recruit-
ment to sites of DNA damage along with other NuRD
components. Notably, CHD4 phosphorylation did not affect
CHD4 interactions with the NuRD subunits MTA2 or HDAC1
(Supplementary Figure S4C and D). In addition, consistent
Figure 2 PARP-dependent recruitment of CHD4 to sites of DNA damage. (A) Immunodetection of CHD4 and gH2AX (damage sites) at the
indicated times after laser micro-irradiation in U2OS (left) and A-Tcells (right). Cells were pre-incubated for 1h with the indicated inhibitors
(ATMi, ATM inhibitor; PARPi, PARP inhibitor) before micro-irradiation. (B) PAR-binding assay with immunoprecipitated GFP-CHD4 wild-type
(WT: residues 1–1937) or truncated mutants (N: residues 1–758; C: residues 1183–1937). GFP only is used as a negative control and GFP-APLF
as a positive control. Right panel: corresponding Ponceau staining of the blot after immunoprecipitation from HEK-293 cells. (C) Recruitment of
GFP-CHD4 wild-type (WT) or a truncated mutant (C: residues 1183–1937) to sites of laser-induced damage (gH2AX) 5min after micro-
irradiation in U2OS cells. In all cases, detergent pre-extraction was performed before ﬁxation of the cells for immunostaining. Scale bars, 10mm.
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accumulation at DNA-damage sites, mutation of the ATM-
target Ser-1346 did not interfere with CHD4 recruitment
(Figure 4A). Furthermore, CHD4 phosphorylation after
exposing cells to IR did not detectably alter its afﬁnity for
PAR (Figure 4B). Reciprocally, preventing CHD4 recruitment
to damaged chromatin by PARP inhibition (Figure 4C) or
deletion of the CHD4 amino-terminus (Figure 4D) did not
impair its phosphorylation. Together, these data established
that ATM-dependent CHD4 phosphorylation and PARP-
dependent CHD4 recruitment to damaged chromatin are
distinct events.
CHD4 regulates cellular sensitivity to DNA damage
To address the biological signiﬁcance of CHD4 to the DDR, we
analysed the effects of its depletion, focusing initially on
PARP-mediated repair of DNA breaks (Caldecott, 2008) and
ATM-dependent signalling. Notably, CHD4 depletion did not
Figure 4 DNA-damage-induced phosphorylation and recruitment of CHD4 to DNA lesions are distinct events. (A) Recruitment of HA-CHD4
wild-type (WT) and Ser-1346 point mutants (SA, mutated to Ala; SE, mutated to Glu) to sites of laser-induced damage (gH2AX) in transiently
transfected U2OS cells 5min after micro-irradiation. Scale bar, 10mm. (B) PAR-binding activity of GFP-CHD4 from HEK-293 cells exposed or not
to ionizing radiation (IR). GFP only is used as a negative control, GFP-APLF as a positive control. Lower panel shows CHD4 phosphorylation
after IR analysed in parallel by western blotting. (C) Detection of CHD4 phosphorylation (aphos-Ab) 30min after exposure to 10Gy ionizing
radiation (IR) or 500mM hydrogen peroxide (H2O2) on CHD4 immunoprecipitates from HEK-293 cells treated or not with PARP inhibitor
(PARPi). SMC1 phosphorylation is used as a control for DNA damage. The NuRD subunit HDAC1 co-immunoprecipitates with CHD4.
(D) Detection of CHD4 phosphorylation (aphos-Ab) 30min after exposure to 10Gy ionizing radiation (IR) on GFP immunoprecipitates from
H3K293 cells transiently expressing GFP-CHD4 wild-type (WT) or a truncated mutant (C: residues 1183–1937).
Figure 3 ATM-dependent phosphorylation of CHD4 Ser-1346 in response to DNA damage. (A) Detection of CHD4 phosphorylation (aphos-Ab)
1h after exposure to 10Gy ionizing radiation (þ IR) on HA immunoprecipitates from U2OS cells transiently expressing HA-CHD4 wild-type
(WT) or S1346A point mutant (SA). The scheme represents CHD4 protein with the amino-acid position of the candidate phospho-serine
(S1346); the N and C fragments correspond to CHD4 truncated mutants analysed in Figures 2 and 4. Domain organization of CHD4: NLS
(putative nuclear localization signal), PHD (plant homeodomain), CHROMO (chromodomain), DEXH (ATP-binding domain), HELIC (helicase
carboxyl-terminal domain). (B) Detection of CHD4 S1346 phosphorylation (aphos-Ab) 30min after cell exposure to 10Gy ionizing radiation
(IR) on HA immunoprecipitates from U2OS cells transiently expressing HA-CHD4. Cells were pre-treated with the indicated inhibitors
(W, Wortmannin; PKi, DNA-PK inhibitor; ATMi, ATM inhibitor). ATM-dependent phosphorylation of SMC1 S966 and DNA-PKcs autophos-
phorylation on S2056 are used as controls.
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recruitment to DNA-damage sites (Supplementary Figure S5A
and B), and did not appreciably affect the recruitment or
dissociation of the SSB repair factor XRCC1 at sites of laser
damage (Supplementary Figure S5C). In line with this, CHD4-
depleted cells efﬁciently repaired DNA breaks arising from
H2O2 exposure as measured by alkaline comet assays
(Supplementary Figure S5D). In addition, we found that
CHD4 depletion did not impair H2AX phosphorylation and
focus formation, the phosphorylation/dephosphorylation ki-
netics of the ATM-targets SMC1 and Chk2 in response to IR
(Figure 5A and B), or the recruitment of the ATM-responsive
checkpoint mediators MDC1, 53BP1 and BRCA1 to laser-
induced and IR-induced DNA damage (Figure 5C and data
Figure 5 CHD4 regulates cell sensitivity to DNA damage. (A) gH2AX foci formation in U2OS cells upon CHD4 depletion (siCHD4) compared
with control (siLuci) 1h after exposure to 10Gy ionizing radiation (IR). (B) Phosphorylation of DNA-damage checkpoint proteins analysed by
western blotting of total extracts prepared from HeLa cells at the indicated times after cell exposure to 10Gy ionizing radiation (IR) (siCHD4,
CHD4 depletion; siLuci, control). (C) Recruitment of MDC1, 53BP1 and BRCA1 to sites of laser-induced damage (gH2AX) 5–10min after micro-
irradiation in HeLa cells upon CHD4 depletion (siCHD4) compared with control (siLuci). Detergent pre-extraction was performed before
ﬁxation and immunostaining for BRCA1. Scale bars, 10mm. (D) Efﬁciency of DSB repair in control (siLuci) or CHD4-depleted U2OS cells
analysed by neutral comet assay after phleomycin treatment (Phleo). Error bars: s.d. from two independent experiments. (E) Clonogenic
survival of U2OS cells upon CHD4 knock-down (siCHD4) compared with control (siLuci) in response to ionizing radiation (IR) or hydrogen
peroxide (H2O2). H2O2 treatment was for 10min at the indicated doses. Error bars indicate s.d. from two and three independent experiments,
respectively. The results are normalized to plating efﬁciencies to focus on the effect of CHD4 depletion upon DNA damage. Note that in the
absence of DNA-damaging agent, the viability of CHD4-depleted cells is B66% of that of control cells.
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cells did not display signiﬁcant defects in G2/M DNA-damage
checkpoint activation or checkpoint recovery (Supplemen-
tary Figure S6). Importantly, however, we observed persis-
tence of IR-induced H2AX phosphorylation in CHD4-depleted
cells (Figure 5B), suggesting that such cells are defective in
DSB repair. To directly address this possibility, we performed
neutral comet assays. Thus, we found that CHD4 depletion
signiﬁcantly impaired the repair of DSBs produced by the
radiomimetic agent phleomycin (Figure 5D). In line with
these ﬁndings, siRNA-mediated CHD4 depletion also signiﬁ-
cantly compromised clonogenic cell survival after exposure
to IR (Figure 5E). Furthermore, CHD4 depletion led to sub-
stantially enhanced cell killing in response to H2O2 treatment
both in U2OS and HeLa cells (Figure 5E and data not shown).
As discussed further below, these results revealed that, while
CHD4 depletion does not overtly impair ATM-dependent
signalling and SSB repair—possibly because of partly com-
pensatory chromatin remodelling activities—CHD4 function
clearly promotes DSB repair and cell survival after genotoxic
challenge.
CHD4 controls the G1/S transition by regulating p53
deacetylation
As cell viability in response to DNA damage relies not only on
DNA repair but also on proper cell-cycle control, we investi-
gated whether CHD4 affected cell-cycle progression. During
the course of these studies, we noticed that in most cell
lines—including U2OS cancer cells and non-cancer cells such
as retinal pigment epithelial cells—CHD4 depletion resulted
in a signiﬁcant block or delay at the G1/S cell-cycle transition
(Figure 6A and data not shown). Given that a master regu-
lator of the passage from G1 to S is the p53-p21 pathway, this
prompted us to examine the regulation of this pathway in
CHD4-depleted cells. Strikingly, this revealed that CHD4
depletion caused a rapid and substantial accumulation of
p21 protein (Figure 6B). The elevation of p21 expression upon
CHD4 depletion was also observed at the RNA level
(Figure 6C) and was restricted to p53 proﬁcient cells
(Figure 6D; Supplementary Figure S7A). Furthermore, we
found that p21 induction was generally accompanied by
heightened p53 protein levels (Figure 6B and E) and corre-
lated with increased p53 binding to the p21 promoter
(Supplementary Figure S7B). Although one potential expla-
nation for these ﬁndings was that p53-dependent transcrip-
tional induction of p21 arises as a consequence of
endogenous DNA damage that can accumulate in CHD4-
depleted cells (Pegoraro et al, 2009; Figure 5D), several
lines of evidence argue against this. First, p21 accumulation
was observed very early upon CHD4 depletion, before a
detectable increase in gH2AX signal (Supplementary Figure
S7C), while accumulation of endogenous DNA damage was
generally observed only from 72h siRNA treatment onwards
(Figure 5D and data not shown). Moreover, contrary to IR-
induced p21 expression, the induction of p21 after CHD4
depletion was not prevented by inhibition of ATM or the
other apical DDR kinases ATR and DNA-PK (Supplementary
Figure S7D and data not shown).
To gain insights into how CHD4 depletion leads to
p53-dependent p21 transcription before the induction of
detectable DNA damage, we analysed p53 modiﬁcations
known to be associated with its transcriptional activity.
Consistent with CHD4 depletion not rapidly triggering p53
activity through the induction of DNA damage, p53 phos-
phorylation on Ser-15 was almost undetectable in CHD4-
depleted cells before exposure to exogenous damage
(Figure 6E). In contrast, we readily detected Lys-382 acetyla-
tion on stabilized p53 in these cells, indicating that CHD4 is
needed for restraining basal levels of p53 acetylation
(Figure 6E). Consistent with this, we found that depletion
of the p300 acetyltransferase, which is responsible for p53
Lys-382 acetylation (Carter and Vousden, 2009; Kruse and
Gu, 2009), reduced both p53 acetylation and p21 levels, and
moreover, rescued cell-cycle progression in CHD4-depleted
cells (Figure 6F and G), supporting the importance of
acetylation in this cell-cycle arrest. Collectively, these ﬁnd-
ings established that CHD4 represses p53-dependent p21
transcription and deﬁne CHD4 as an important regulator of
the G1 to S transition through controlling p53 deacetylation.
Discussion
CHD4 is well characterized as a catalytic subunit of the NuRD
transcriptional repressor complex (Wade et al, 1998; Xue
et al, 1998; Zhang et al, 1998; Denslow and Wade, 2007;
Ramirez and Hagman, 2009). Here, we have uncovered new
functions for CHD4 in genome stability and cell-cycle pro-
gression. Speciﬁcally, we have shown that CHD4 is an
important contributor to multiple aspects of the DDR. The
recruitment of CHD4 to DNA-damage sites in a PARP-depen-
dent manner and the hyper-sensitivity of CHD4-depleted cells
to H2O2 strongly suggest that CHD4 responds to SSBs and
possibly oxidative DNA damage, whereas CHD4 phospho-
rylation by ATM points to additional functions in response to
DSBs. Consistent with such a DSB repair function, we have
observed that CHD4-depleted cells are hyper-sensitive to IR,
display delayed removal of gH2AX after IR exposure and are
deﬁcient in repairing DSBs as detected by neutral comet
assays. Furthermore, we have established an important func-
tion for CHD4 in cell-cycle control at the G1/S transition by
regulating p53 deacetylation. It will be interesting to examine
whether these functions of CHD4 are distinct, or whether
they operate in antagonistic or inter-dependent ways. In
particular, CHD4 functions in DSB repair and p53-dependent
cell-cycle control are both likely to promote the survival of
damaged cells, and their relative contributions need to be
further clariﬁed. Notably, we have also observed that ATM
inhibition enhances CHD4 accumulation at DNA-damage
sites. As ATM phosphorylates CHD4, this result initially
suggested to us that phosphorylation might regulate the
dissociation kinetics of CHD4 from damage sites. However,
we did not observe signiﬁcant differences in the timing and
level of accumulation between wild-type CHD4 and a mutant
CHD4 derivative in which the Ser-1346 ATM-target site was
mutated. Thus, our interpretation of the effect of ATM
inhibitor is that it promotes CHD4 accumulation indirectly
by enhancing the PAR signal at DNA-damage sites (shown in
Supplementary Figure S1F).
In regards to CHD4 functioning to regulate p53 deacetyla-
tion, the mechanism is unlikely to be direct given that CHD4
itself does not display acetyltransferase or deacetylase
activities. However, it is noteworthy that, within the NuRD
complex, CHD4 associates with HDAC1, an enzyme directly
implicated with MTA2 in p53 deacetylation and whose
CHD4 and genome stability
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et al, 2002). Importantly, our data show that HDAC1 and
MTA2 levels are unaffected by CHD4 depletion, supporting
the idea that CHD4 controls the G1/S cell-cycle transition by
promoting the ability of HDAC1 to deacetylate p53. In addi-
tion to a function in cell-cycle control, the recruitment of
CHD4 and other components of the NuRD complex to DNA
breaks indicates that NuRD also has important functions at
DNA-damage sites, in particular to ensure efﬁcient repair of
DSBs. Although deciphering the underlying mechanism for
such a repair function still requires further investigation, it is
tempting to speculate that this could be through local remo-
delling of chromatin to facilitate DNA repair, perhaps in ways
similar to those proposed for yeast and other mammalian
chromatin remodelling complexes (Park et al, 2006; Ahel
et al, 2009; Peng et al, 2009; Sinha et al, 2009). Another
possible function for NuRD at DNA-damage sites is to ensure
that transcription is locally inhibited, thus preventing
transcription from interfering with DNA-damage signalling
and/or repair. Interestingly, CHD4 appears to be one of the
several, and possibly many, chromatin remodelling factors
recruited to DNA breaks in mammalian cells (Murr et al,
2006; Ahel et al, 2009; Gottschalk et al, 2009; Peng et al,
2009; Timinszky et al, 2009). It is, therefore, possible that
such factors will display synergistic and/or antagonistic
functions in the regulation of chromatin compaction at
DNA-damage sites, as happens in the context of transcription
(Ramirez-Carrozzi et al, 2006; Clapier and Cairns, 2009).
Figure 6 CHD4 controls the G1/S cell-cycle transition through p53 deacetylation. (A) Fluorescence-activated cell sorting (FACS) proﬁles of
U2OS cells downregulated for CHD4 (siCHD4) compared with control (siLuci). Percentages of cells in G1 are indicated. Nocodazole was used to
block cell-cycle progression in mitosis (bottom panels). (B) Western-blot analysis of total extracts from U2OS cells downregulated for CHD4
(siCHD4) compared with control (siLuci) using the indicated antibodies. (C) Quantitative RT–PCR analysis of p21, p53 and b-actin mRNA levels
in U2OS cells downregulated for CHD4 (siCHD4) compared with control (siLuci). Error bars indicate s.d. from two independent experiments.
(D) Western-blot analysis of p21 induction on total extracts from p53 proﬁcient or deﬁcient HCT116 cells upon CHD4 depletion (C) compared
with control siLuciferase (L). þ IR: 9h post-exposure to 10Gy IR. (E, F) Western-blot analysis of total extracts from U2OS cells treated with the
indicated siRNAs. Phleo: 1h post-exposure to 60mg/ml Phleomycin. (G) FACS proﬁles of U2OS cells treated with the indicated siRNAs.
Nocodazole was used to block cell-cycle progression in mitosis.
CHD4 and genome stability
SE Polo et al
The EMBO Journal VOL 29 | NO 18 | 2010 &2010 European Molecular Biology Organization 3136Although such relationships will be of interest to explore in
future studies, they may pose technical challenges because
deﬁning clear functions for individual chromatin remodelling
components will likely require the combined inactivation of
functionally overlapping, partially redundant complexes.
Collectively, the data we have provided deﬁne CHD4 as a
new player in the DDR and in p53-dependent cell-cycle
control. These ﬁndings thereby help explain recent observa-
tions linking NuRD to cellular ageing (Pegoraro et al, 2009)
and might shed light on why patients expressing auto-
antibodies against CHD4 display higher cancer incidence
(Hill et al, 2001). Deﬁning DDR functions for CHD4 and
other chromatin remodelling components is also relevant
for cancer research in general, given that drugs targeting
chromatin-modifying enzymes are being explored as anti-
cancer therapies, both for use alone and in combination with
DNA-damaging treatments (Ellis et al, 2009).
Materials and methods
Cell culture and transfections
Human U2OS, HEK-293, BJ, HeLa, A-T (from Y Shiloh), p53
þ/þ
and p53
 /  HCT116 cells (from B Vogelstein), H2AX
þ/þ and
H2AX
 /  mouse embryonic ﬁbroblasts (from A Nussenzweig) were
grown in Dulbecco’s modiﬁed Eagle medium (Invitrogen) supple-
mented with 10% foetal bovine serum (BioSera), 2mM L-glutamine,
100unit/ml penicillin, 100mg/ml streptomycin and fungizone
(Sigma-Aldrich). Cell transfections with plasmid DNA or siRNA
duplexes (Supplementary Table S2) were performed by using
Lipofectamine 2000 and Lipofectamine RNAiMax (Invitrogen),
respectively, following the manufacturer’s instructions. Cells were
analysed 48–72h after transfection.
Antibodies
All the antibodies used in this study are commercially available
(detailed in Supplementary Table S1) except the phospho-speciﬁc
antibody used against CHD4, which was provided by Y Shiloh.
Plasmids
An IMAGE clone corresponding to the full-length human CHD4
cDNA (isoform 2, accession number BC038596, clone 5528023 in
pCMV-sport6 vector, Geneservice Ltd.) was used to generate
plasmids encoding HA-CHD4 and GFP-HA-CHD4 wild-type, trun-
cated mutants (N, C) and point mutants (S1346A, S1346E). The HA
tag replaced CHD4 50UTR region. The GFP sequence was PCR
ampliﬁed from pEGFP-C1 (Clontech). An NLS sequence was
included in CHD4 construct lacking the amino-terminal domain to
ensure proper nuclear localization. All constructs were veriﬁed by
direct sequencing and/or restriction digests. Cloning details and
primer sequences (Sigma-Aldrich) are available upon request.
GFP-APLF plasmid was described in Ahel et al (2008).
DNA damage and drug treatments
ATM (KU-55933) (Hickson et al, 2004), PARP (KU-58948) (Farmer
et al, 2005) and DNA-PK (NU-7441) (Leahy et al, 2004) inhibitors
(KuDOS Pharmaceuticals Ltd.) were used at a ﬁnal concentration of
20, 10 and 2mM, respectively. Wortmannin (Alexis Biochemicals)
was used at 200mM to inhibit ATM, ATR and DNA-PK. Inhibitors
were applied to culture medium 1h before subsequent treatments.
IR was delivered by an X-ray generator (Faxitron X-ray Corporation
RX-650, 120kV, 5mA, dose rates 10 and 5.3Gy/min). Treatment
with H2O2 (VWR) was for 30min at 500mM unless otherwise stated.
Treatment with phleomycin (Melford Laboratories) was for 1h at
60mg/ml. Nocodazole (Sigma-Aldrich) was used at a ﬁnal
concentration of 40ng/ml for 20h.
Laser micro-irradiation
Localized DNA damage was generated by exposure of cells to a
UV-A laser (Limoli and Ward, 1993; Lukas et al, 2003). Cells plated
on glass-bottom dishes (Willco Wells) were pre-sensitized with
10 mM 5-bromo-20-deoxyuridine (BrdU, Sigma-Aldrich) in phenol
red-free medium (Invitrogen) for 24h at 371C. Micro-irradiation was
performed with a FluoView 1000 confocal microscope (Olympus)
equipped with a 371C heating stage (Ibidi) and a 405-nm laser diode
(6mW) focused through a 60X UPlanSApo/1.35 oil objective to
yield a spot size of 0.5–1mm. Time of cell exposure to the laser
beam was B250ms (fast-scanning mode). Laser settings (0.40mW
output, 50 scans, SIM scanner) were chosen to generate a detectable
DDR restricted to the laser path in a pre-sensitization-dependent
manner without detectable cytotoxic effects.
Immunoﬂuorescence
Cells on glass coverslips (VWR) or glass-bottom dishes (Willco
Wells) were ﬁxed with 2% paraformaldehyde and permeablized
with 0.2% Triton-X-100 in PBS. When indicated, permeabilization
was carried out before ﬁxation in 10mM PIPES pH 7.0, 100mM
NaCl, 300mM sucrose, 3mM MgCl2, 0.5% Triton-X-100 for 5min at
room temperature. Samples were then blocked in 5% bovine serum
albumin and stained with the appropriate primary (Supplementary
Table S1) and secondary antibodies coupled to AlexaFluor 488 or
594 (Molecular Probes). Confocal images were captured on a Nikon
Eclipse E800 microscope equipped with Radiance 2100 laser set-up
and LaserSharp software (Bio-Rad) or on FluoView1000 Olympus
using a  40 or  60 oil objective. To avoid bleed-through effects in
double-staining experiments, each dye was scanned independently
in a multi-tracking mode.
Immunoblotting
Total cell extracts were obtained by scraping cells in Laemmli buffer
(0.8% SDS, 4% glycerol, 280mM b-mercaptoethanol, 25mM Tris–
HCl pH 6.8, 0.005% bromophenol blue). Proteins were resolved by
SDS–PAGE, transferred onto nitrocellulose (Protran) and probed
using the appropriate primary (Supplementary Table S1) and
secondary antibodies coupled to horse-radish peroxidase (Dako,
Pierce). Protein detection was performed with ECL reagents (GE
Healthcare).
Immunoprecipitation
Cells harvested in PBS were lysed in RIPA buffer (10mM Tris pH 8,
1% Triton-X-100, 0.1% deoxycholate, 0.1% SDS, 150mM NaCl) or
lysis buffer (20mM Tris pH 7.5, 40mM NaCl, 2mM MgCl2, 0.5%
NP-40, 50U/ml benzonase) supplemented with protease and
phosphatase inhibitors and adjusted to 450mM salt concentration.
Lysates were clariﬁed by centrifugation (13200r.p.m., 20min, 41C)
and 500mg–1mg proteins were used per immunoprecipitation in
RIPA buffer or IP buffer (25mM Tris pH 7.5, 150mM NaCl, 1.5mM
DTT, 10% glycerol, 0.5% NP-40) supplemented with protease and
phosphatase inhibitors. Proteins were captured with the appropriate
antibody and protein A-sepharose Fast-Flow (Sigma) or Dynabeads
(Dynal), or directly onto GFP-Trap agarose beads (ChromoTek) for
GFP-tagged proteins. Complexes were extensively washed in RIPA
or IP buffer. Immunoprecipitation with rabbit serum or from cells
that do not express epitope-tagged protein were used as negative
controls.
PAR-binding assay
GFP-tagged proteins transiently expressed in human HEK-293 cells
were isolated with GFP-Trap beads (ChromoTek) following the
above-described immunoprecipitation procedure. Immunoprecipi-
tates were extensively washed in RIPA buffer adjusted to 1M NaCl
to disrupt protein complexes, before incubation for 1h in Tris-
buffered saline—0.1% Tween containing 100nM puriﬁed PAR
(Alexis Biochemicals). After extensive washes in TBS-Tween
adjusted to 300mM NaCl, complexes were resuspended in Laemmli
buffer, boiled and spotted onto nitrocellulose for immunodetection
with anti-GFP and anti-PAR antibodies.
Comet assays
Cells were treated with 150mMH 2O2 in PBS for 10min on ice or
with 60mg/ml phleomycin for 2h at 371C followed by 1h recovery
in culture medium at 371C. Alkaline and neutral comet assays were
as speciﬁed in the Comet Assay kit (Trevigen) using GelBond ﬁlms
(Lonza) to support agarose gels. Samples stained with SYBR–Green
I were observed under an epiﬂuorescence microscope (Olympus
IX71) using a UPlanFLN  10 objective. Images were analysed
with CometScore software (TriTek) by scoring around 100 cells in
each case.
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RNA extracted with Trizol (Invitrogen) was subject to DNA
digestion with Turbo enzyme (Ambion) and reverse transcription
with Superscript III RT (Invitrogen). DNA products were quantiﬁed
by real-time PCR on ABI Prism 7000 sequence detection system
(Applied Biosystems) using SYBR–Green mix with the indicated
primer pairs (Supplementary Table S3).
Fluorescence-activated cell sorting
Cells were ﬁxed in ice-cold 70% ethanol. DNA was stained with
50mg/ml propidium iodide (Sigma-Aldrich) in PBS containing 0.1%
Triton-X-100 and 0.5mg/ml DNAse-free RNAse A (Sigma-Aldrich).
Samples were processed on an FACSCalibur ﬂow cytometer
equipped with CellQuest software (Becton Dickinson). The results
were analysed using FlowJo software (TreeStar).
Colony-forming assays
Forty-eight hours after siRNA transfection, cells were replated and
exposed to the indicated DNA-damaging agent the following day.
After an additional 14-day incubation, colonies were stained with
0.5% crystal violet/20% ethanol and counted. The results were
normalized to plating efﬁciencies.
Supplementary data
Supplementary data are available at The EMBO Journal Online
(http://www.embojournal.org).
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